Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 314

1.

The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.

Julià M, Guilabert A, Lozano F, Suarez-Casasús B, Moreno N, Carrascosa JM, Ferrándiz C, Pedrosa E, Alsina-Gibert M, Mascaró JM Jr.

JAMA Dermatol. 2013 Sep;149(9):1033-9. doi: 10.1001/jamadermatol.2013.4632.

PMID:
24048425
2.

Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.

Kyriakou A, Patsatsi A, Sotiriadis D.

J Dermatolog Treat. 2013 Jun;24(3):162-8. doi: 10.3109/09546634.2011.646939. Epub 2012 Jan 4.

PMID:
22136334
3.
4.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

5.

The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.

Gallo E, Cabaleiro T, Román M, Solano-López G, Abad-Santos F, García-Díez A, Daudén E.

Br J Dermatol. 2013 Oct;169(4):819-29. doi: 10.1111/bjd.12425.

PMID:
23662788
6.

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.

Esposito M, Gisondi P, Cassano N, Ferrucci G, Del Giglio M, Loconsole F, Giunta A, Vena GA, Chimenti S, Girolomoni G.

Br J Dermatol. 2013 Sep;169(3):666-72. doi: 10.1111/bjd.12422.

PMID:
23647206
7.

Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.

Mossner R, Reich K.

Curr Probl Dermatol. 2009;38:107-36. doi: 10.1159/000232307. Epub 2009 Jul 28. Review.

PMID:
19710553
8.

Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.

Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.

J Drugs Dermatol. 2013 Aug;12(8):874-80.

PMID:
23986160
10.

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.

Gniadecki R, Kragballe K, Dam TN, Skov L.

Br J Dermatol. 2011 May;164(5):1091-6. doi: 10.1111/j.1365-2133.2011.10213.x. Epub 2011 Apr 11.

PMID:
21219290
11.

Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis.

Ryan C, Kelleher J, Fagan MF, Rogers S, Collins P, Barker JN, Allen M, Hagan R, Renfro L, Kirby B.

Clin Exp Dermatol. 2014 Jun;39(4):519-24. doi: 10.1111/ced.12323. Epub 2014 Apr 23.

PMID:
24758522
12.

Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.

Morales-Lara MJ, Cañete JD, Torres-Moreno D, Hernández MV, Pedrero F, Celis R, García-Simón MS, Conesa-Zamora P.

Joint Bone Spine. 2012 Dec;79(6):591-6. doi: 10.1016/j.jbspin.2012.02.003. Epub 2012 Apr 4.

PMID:
22480748
13.

Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study.

Di Lernia V, Ricci C, Lallas A, Ficarelli E.

J Dermatolog Treat. 2014 Feb;25(1):73-4. doi: 10.3109/09546634.2013.800184. Epub 2013 May 21.

PMID:
23621374
14.

TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis.

Murdaca G, Gulli R, Spanò F, Lantieri F, Burlando M, Parodi A, Mandich P, Puppo F.

J Invest Dermatol. 2014 Oct;134(10):2503-2509. doi: 10.1038/jid.2014.123. Epub 2014 Mar 4.

15.

Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.

Hoffmann JH, Knoop C, Enk AH, Hadaschik EN.

J Dermatol Sci. 2014 Dec;76(3):180-5. doi: 10.1016/j.jdermsci.2014.09.003. Epub 2014 Sep 28.

PMID:
25306295
16.

Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.

Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.

Br J Dermatol. 2010 Oct;163(4):838-46. doi: 10.1111/j.1365-2133.2010.09950.x. Epub 2010 Sep 2.

PMID:
20649798
17.

Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.

Vasilopoulos Y, Manolika M, Zafiriou E, Sarafidou T, Bagiatis V, Krüger-Krasagaki S, Tosca A, Patsatsi A, Sotiriadis D, Mamuris Z, Roussaki-Schulze A.

Mol Diagn Ther. 2012 Feb 1;16(1):29-34. doi: 10.2165/11594660-000000000-00000.

PMID:
22111980
18.

Treatment of generalized vitiligo with anti-TNF-α Agents.

Alghamdi KM, Khurrum H, Taieb A, Ezzedine K.

J Drugs Dermatol. 2012 Apr;11(4):534-9.

PMID:
22453596
19.

Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.

Woolf RT, Smith CH, Robertson K, Barker JN.

Br J Dermatol. 2010 Oct;163(4):889-92. doi: 10.1111/j.1365-2133.2010.09893.x. Epub 2010 Jul 28. Review. No abstract available.

PMID:
20854408
20.

Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.

Leman J, Burden AD.

Br J Dermatol. 2012 Nov;167 Suppl 3:12-20. doi: 10.1111/j.1365-2133.2012.11209.x. Review.

PMID:
23082811

Supplemental Content

Support Center